Bcl2 is not required for the development and maintenance of leukemia stem cells in mice.
González-Herrero
Inés
I
Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas/Universidad de Salamanca, Campus Miguel Unamuno sin número, 37007 Salamanca, Spain.
Vicente-Dueñas
Carolina
C
Orfao
Alberto
A
Flores
Teresa
T
Jiménez
Rafael
R
Cobaleda
César
C
Sánchez-García
Isidro
I
D000818:Animals; D000950:Antigens, Ly / Q000502:physiology; D001549:Benzamides; D004195:Disease Models, Animal; D016044:Fusion Proteins, bcr-abl / Q000502:physiology; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology*; D008565:Membrane Proteins / Q000502:physiology; D051379:Mice; D014411:Neoplastic Stem Cells / Q000473:pathology*; D010879:Piperazines / Q000627:therapeutic use; D011518:Proto-Oncogene Proteins / Q000502:physiology*; D019253:Proto-Oncogene Proteins c-bcl-2; D011743:Pyrimidines / Q000627:therapeutic use
D000950:Antigens, Ly; D001549:Benzamides; C074650:Ly6a protein, mouse; D008565:Membrane Proteins; D010879:Piperazines; D011518:Proto-Oncogene Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D011743:Pyrimidines; C052617:Bcl2 protein, mouse; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl